

## Keyword Index for Volume 93

- 5-aminolevulinic acid 1137  
5-fluorouracil 993  
5-fluorouracil modulation 896  
5-FU 185  
5T4 670
- ablation 890  
abnormal p53 protein  
  expression 946  
actigraphy 1202  
acute lymphoblastic leukaemia  
  379  
adenocarcinoma 450, 1301  
adiponectin 811  
adjuvant chemotherapy 627,  
  884, 896  
adjuvant endocrine therapy  
  1319  
adolescence 817  
adriamycin 544  
advanced breast cancer 515  
advanced head and neck cancer  
  884  
advanced pancreatic cancer 185  
adverse skeletal events 633  
aetiology 842  
affinity 1257  
Africa 1068  
age adjustment 372  
age–period–cohort 1077  
AKT 1372  
all-cause mortality 392  
alternative medicine 538  
amplification 699  
anaemia 224  
angiocidin 662  
angiogenesis 613, 781, 793, 855,  
  1128, 1350, 1356  
angiotensin I/II 425  
angiotensin-converting  
  enzyme 602  
anoikis 233  
anthropometry 1310  
antiangiogenic therapy 876  
antibody 1085  
antibody response 458  
anti-Fas monoclonal  
  antibody 544  
anti-late-diarrhoeal  
  program 1341  
antisense RNA 216  
apoptosis 1, 70, 208, 233, 973,  
  1157, 1356  
array CGH 699, 1191  
arterial infusion  
  chemotherapy 557  
association 493  
ATM heterozygosity 260  
aurora 719
- basal cell carcinoma 597  
Bayesian methods 1077
- betel quid 602  
biobank 834  
biomarkers 735  
BK virus 1305  
bladder 346  
bladder cancer 804, 1182  
bleomycin 1209  
blood flow 98  
body fatness 817  
body mass 1057  
body mass index 807, 811, 1310  
bone metastases 633  
bone morphogenetic  
  proteins 850  
brain tumours 152, 781  
*BRCA1* 287  
*BRCA2* 287  
breast cancer 167, 287, 293, 364,  
  392, 406, 520, 590, 627, 694,  
  699, 793, 817, 924, 973, 1005,  
  1062, 1128, 1152, 1168, 1215,  
  1295, 1372  
breast cancer mortality 392  
breast cancer stage 1046  
breast carcinoma 1046  
breast neoplasm 582, 1122  
breast tumour xenografts 1152  
breast-conserving  
  surgery 520, 1122  
breastfeeding 379  
buccal biopsy 208  
burnout 1092
- CA19-9 195, 740  
cachexia 774  
calcium 639, 1364  
calcium sensing receptor 1364  
calprotectin 639  
cancer cachexia 425  
cancer of the small intestine 807  
cancer of the testis 909  
cancer predisposition 260  
cancer registries 159, 372  
cancer vaccine 1250  
capecitabine 510, 1117  
carbonic anhydrase IX 1267  
carboplatin 1209  
carcinogenesis 331  
carcinoid 1144  
carcinomas 346, 464  
cardia 859  
case–control 167  
case–control study 1057  
CD146 793  
CD34+ cell 855  
CD4 and CD8 lymphocytes 435  
cell cycle 939  
cervical cancer 376, 862, 1077  
cervix 1301  
chemoprevention 735  
chemoradiotherapy 652, 1117
- chemotherapy 29, 54, 224, 233,  
  279, 302, 483, 740, 744, 909,  
  977  
chemotherapy resistance 510  
chemotherapy response 515  
child 379  
childhood 817  
childhood acute lymphoblastic  
  leukaemia 1307  
childhood acute myeloid  
  leukaemia 1388  
childhood and adolescent  
  cancer 1038  
childhood chronic diseases  
  1053  
children 412  
chimeric immune receptor 1085  
chromosomal radiosensitivity  
  1038  
CIN 248  
circadian function 1202  
circulating endothelial cells 793  
cisplatin 178, 529, 678, 763,  
  909, 1112, 1117, 1209,  
  1341, 1356  
ckit 107  
clinical guidelines 1122  
clinical trials 41  
clonogenic assay 70  
coffee 607  
cohort studies 804, 807, 1053,  
  1310  
colon cancer 338, 1356  
colon carcinoma 1364  
colonic cancer 1062  
colorectal adenomas 954  
colorectal cancer 1, 399, 510,  
  744, 799, 896, 1230, 1236  
comorbidities 1098  
contrast agent 131  
C-reactive protein 639  
CRM 529  
CT antigen 458  
cutaneous melanoma 597  
CXCR4 924  
cyclin A 515  
cyclin D1, D2, D3 338  
cyclooxygenase-2 954  
cytarabine 1388  
cytidine deaminase 35  
cytochrome P450 973  
cytology 1175  
cytoskeleton 499  
cytotoxic 979
- darbepoetin alfa 224  
DCE-MRI 979  
Decoy receptor 3 544  
deletion 699  
dendritic cell 749  
deoxynucleoside analogues  
  1388
- dependence receptor 1  
deprivation 622  
diabetes mellitus 1310  
diagnosis 399, 905  
differentiation 338, 450, 1364  
disease grade 248  
disease-free survival 453  
DNA microarray 1182  
DNA replication licensing 1295  
DNA sequence 1068  
DNA vaccination 1250  
DNA-PK 1011  
docetaxel 173, 999  
dose density 7  
doxil 46  
doxorubicin 89  
*DRM/Gremlin (CKTSF1B1)* 1029  
drug assessment end points 504  
drug delivery 224  
drug resistance 483  
drug therapy 735  
ductal carcinoma *in situ* 1122  
dysadherin 1382
- early breast cancer 1319  
early-onset breast cancer 260  
E-cadherin 1364, 1382  
ectodomain shedding 1267  
ED1 and ED2 macrophages  
  435  
EGFR 107, 124, 915, 1334  
EGFRvIII 915  
elastase 1024  
elderly 770  
ELISPOT 248  
embryonal carcinoma 1382  
EMEA 504  
endometrial cancer 999, 1062  
endostatin 1024  
endothelial progenitor cell 855  
endothelin-1 98  
EORTC 387  
eprh-in-A1 933  
EPIC 1305  
epidemiology 811, 838, 842  
epidermal growth factor  
  receptor 355  
epigenetic inactivation 850  
epirubicin 406  
EPR effect 678  
erbB-2 7  
erythropoietin 224, 1350  
ET<sub>A</sub> and ET<sub>B</sub> receptors  
  distribution 98  
ET<sub>B</sub> agonist IRL 1620 98  
etoposide 216, 1209  
etoposide phosphate 60  
ETS 933  
evaluation 862  
expression profiling 924  
extragonadal germ cell  
  tumour 412

- Fab fragment 1257  
 FAK 694  
 familial cancer 260  
 family history 825, 1307  
 farnesyltransferase inhibitor 1222  
 Fas 544  
 Fas ligand 544  
 FDA 504  
 feasibility 208  
 feasibility study 884  
 febrile neutropenia 1324  
 fertility 200, 859  
 fine-needle aspiration 1175  
 first-line 190  
 fixed dose rate infusion 35  
 flk-1 1005  
 flt-1 1005  
 fluorouracil 190, 1236  
 fluvastatin 319  
 folate 639  
 follicular neoplasms 1175  
 follicular thyroid carcinoma (FTC) 144  
 free fatty acids 639  
  
 galectin-3 1175  
 gastric cancer 688, 986, 1395  
 gastrocnemius muscle 774  
 gefitinib 23, 915, 1334  
 gemcitabine 29, 185, 195, 319, 406, 770, 1112  
 gemcitabine pharmacokinetic 35  
 geminin 1295  
 gene expression 1182, 1277  
 gene expression profiling 310  
 gene microarray 483  
 gene transfer 441  
 genetic epidemiology 167  
 genetic instability 719  
 genetic polymorphism 167  
 germ-cell tumour 909  
 gestational trophoblastic neoplasia 620  
 Gleason grade 1019  
 glioma 124  
 glutathione-S-transferase 216  
 goserelin 647  
 GOT1 1144  
 grade of tumour 946  
 growth arrest 1364  
 GTPase 499  
 guideline adherence 520  
 guidelines 387  
  
 haplotypes 954  
 hazard ratio 607  
 HB-94 538  
 head and neck cancer 1117  
 healing 538  
 hENT1 1388  
 hepatocellular carcinoma 458, 557, 607  
 HER-2 107, 1250  
 HER-2 overexpression 552  
 HER3 1334  
 HHV8 834  
  
 HIF 346  
 HIFU 890  
 high-dose chemotherapy 412, 620  
 high-dose palliative radiotherapy 652  
 high-risk HPV 862  
 histamine dihydrochloride 757  
 histology 364, 1046  
 HL60 human promyelocytic leukaemia 89  
 Hodgkin's lymphoma 571  
 homocysteine 639  
 Hong Kong 1077  
 hormone receptor status 946  
 hormone receptors 364  
 hormone replacement therapy 582  
 hormones 200  
*HPP1* 1029  
 HPV 575, 1068, 1301  
 HPV16 248  
 HT29 338  
 hTERT 116, 152  
 human breast cancer 946  
 human papillomavirus 116, 946  
 hyaluronidase 81  
 hypermethylation 1395  
 hypoxia 224, 346, 1128, 1267, 1356  
  
 ID1 933  
 IFNAR2 557  
 ifosfamide 178  
*IL1-RN* 493  
 immortalisation 116  
 immune response 435  
 immunofluorescence 834  
 immunoglobulin 1257  
 immunohistochemistry (IHC) 107, 144, 453, 464, 478, 688, 1019  
 immunomodulatory 613  
 immunoprevention 1250  
 immunotherapy 458, 670, 749  
*in vitro* fertilisation 1053  
 infection 379  
 inflammation 331, 493  
 inherited predisposition 1038  
 insulin 639  
 integrins 167  
 interferon alpha 441  
 interleukin-2 273, 757  
 intermediate and poor prognosis metastatic germ cell tumours 1209  
 internalisation 1257  
 interstitial fluid pressure 81  
 interstitial laser thermotherapy 435  
 investigation 905  
 iressa 915  
 irinotecan 763, 1106, 1230, 1341  
 isoflavones 15  
  
 Japan Collaborative Cohort Study (JACC Study) 607  
  
 K-ras 355  
*k-ras* mutation 850  
  
 KCNH2 781  
 KCNH3 781  
 KDR 1005  
 keratin 1182  
 keratinocytic cancer 597  
 Ki-67 939, 1295  
 kidney 890  
*K<sup>trans</sup>* 979  
 Kv 11.1 781  
 Kv 12.2 781  
  
 laser capture microdissection 1301  
 LDH 273  
 lenalidomide 613  
 leptin 811  
 leukaemia 379, 973  
 liposomal doxorubicin 81  
 liquid-based cytology 242, 575  
 liver 890  
 local neoplasm recurrence 1122  
 local vegetarian food 1057  
 locally advanced rectal cancer 993  
 LoVo39 338  
 low-risk 1324  
 [<sup>177</sup>Lu-DOTA<sup>0</sup>-Tyr<sup>3</sup>]-octreotate 1144  
 lung adenocarcinoma 355  
 lung cancer 652, 719, 825, 905, 1329  
 lymph node metastasis 924, 1128  
 lymph node micrometastasis 688  
 lymphangiogenesis 1168  
 lymphatic invasion 688  
 lymphatic microvessel density 1168  
 lymphatic tumour dissemination 1168  
 lymphatic vessel invasion 1168  
 lymphoma 1062, 1382  
 LYVE-1 1168  
  
 magnetic resonance imaging 131  
 major depression 1329  
 malignant gliomas 152  
 malignant lymphoma 418  
 malignant transformation 1285  
 mammary tumour 1137  
 mammography 590  
 mantle cell lymphoma (MCL) 939  
 marketing approval 504  
 mastectomy 287, 1122  
 matched case-control study 418  
 matched pairs 694  
 maximum likelihood estimation 1077  
 MCF-7 538, 1005, 1152  
 MCM 1295  
 Mcm2 1295  
 melanoma 216, 933  
 meningiomas 152  
 menopausal status 15, 582  
  
 meta-analysis 825  
 metabolism 1011  
 metachronous colorectal cancer 472  
 metalloproteases 1267  
 metaregression 1215  
 metastases 552  
 metastasis 1244, 1277  
 metastatic gastric cancer 190  
 metastatic germ cell cancer 178  
 metastatic melanoma 273  
 metastatic stage 450  
 methylation 850, 1029  
 MGMT 529, 1152  
 microarray 346  
 microenvironment 302  
 microsatellite instability 472  
 microvascular pressure 81  
 minichromosome maintenance protein 6 (MCM6) 939  
 minimal residual disease 565  
 minor depression 1329  
 mitochondrial DNA 331  
 mitogen-activated protein kinase 1364  
 mitomycin C 510  
 molecular diagnostics 565  
 monoclonal antibody 131  
 monocytes 273, 855  
 mTOR 1372  
 mts1 protein 1277  
 mucin 1257  
 multicellular resistance 302  
 multidisciplinary teams 977, 1092  
 multidrug resistance 46, 89  
 multidrug resistance protein 216  
 multiple myeloma 70, 613, 834  
 muscle wasting 425  
 mutation 915, 1244  
 myelodysplastic syndromes 613  
  
*n*-3 fatty acids 639  
 NADPH cytochrome P450 reductase 89  
 natural killer cell 441  
 NCI 387  
 needle biopsy 478  
 neoplasia 499, 735  
 neoplasm 859  
 nested case-control study 834  
 neuroblastoma 310  
 neuroma, acoustic 842  
 neuronal markers 1197  
 neurotoxicity 678  
 neutrophils 273  
 never-smoker 23  
 NF- $\kappa$ B 1019, 1285  
 non-Hodgkin 1062  
 non-Hodgkin's lymphoma 159, 811  
 nonmelanoma skin cancer 597  
 non-small-cell lung cancer 23, 29, 450, 453, 850, 977, 1098, 1106, 1202, 1334, 1341

- non-small-cell lung carcinoma 137  
 Norway 807  
 Notch 709  
 NSCLC 763, 770, 1157  
 NU7026 1011  
 nuclear factor  $\kappa$ B 70  
 nude mice 1005  
 nurse-managed care 41  
 nutrition 735  
  
 obesity 582, 1062, 1310  
 oesophageal cancer 107, 1112  
 oestrogen 392, 859  
 oestrogen plus progestin 392  
 oestrogen receptor 1046  
 omega-3 fatty acid 1329  
 oncofoetal antigen 670  
 oncofoetal fibronectin mRNA 565  
 oncology drugs 504  
 oral antibiotics 1324  
 oral precancerous lesions 602  
 oral squamous cell carcinoma 1250  
 organised programme 376  
 osteopontin (OPN) 453  
 ovarian adenoma 709  
 ovarian cancer 60, 973  
 ovarian carcinoma 709  
 ovarian neoplasms 647  
 ovarian surface epithelium 116  
 overall survival 453  
 oxaliplatin 29, 190, 993, 1230  
 oxidative stress 331, 757  
  
 p16 933  
 p53 242, 355  
 p53 mutations and ERB-2 expression 946  
 p53 pathway 124  
 p70S6K 1372  
 paclitaxel 178, 1106  
 paediatric phase I/II 529  
 palliative 54  
 palliative benefit 652  
 pancreas 1024  
 pancreatic cancer 35, 195, 441, 740, 1062  
 pancreatic cancer cells 319  
 pancreatic neoplasms 1310  
 papillary thyroid carcinoma (PTC) 144  
 participation in sports 817  
 pathological complete response 406  
 patient mortality 946  
 patient preferences 1319  
 PDK-1 1372  
 pegylated liposomal doxorubicin 46  
 pendrin 144  
 peritoneal metastasis 986  
 P-glycoprotein 973  
 pharmacodynamics 876  
 pharmacokinetics 876, 1011, 1222  
 pharmacology 173  
  
 phase I clinical trial 876  
 phase I study 1222  
 phase II 999, 1112  
 phosphorylation 1372  
 photodynamic detection 1137  
 plasminogen activator inhibitor-1 799  
 polymeric micelle 678  
 polymorphisms 954  
 polyubiquitin 662  
 portal vein thrombosis 557  
 predictive factors 7  
 premenopausal 817  
 prenatal origin 1307  
 preoperative chemoradiation 993  
 prevention 287  
 primary breast cancer 552  
 primary chemotherapy 406  
 primary health care 399  
 probability 1244  
 prognosis 7, 124, 137, 152, 450, 515, 627, 740, 838, 933, 1098  
 prognosis marker 924  
 prognostic 387  
 prognostic factors 273  
 prognostic model 273  
 progression 242  
 proliferation 208, 338, 515, 939  
 prospective studies 986, 1310  
 prostate cancer 478, 493, 633, 749, 1019, 1285, 1305  
 prostate neoplasm 1057  
 proteasome expression 425  
 protein beam 849  
 protein degradation 774  
 proteosome 662  
 protoporphyrin IX 1137  
 PSA 1285  
 PSC 833 46  
 psychological distress 622  
 psychological well being 1092  
 PTEN 124  
 public health 862  
  
 quality of life 200, 1202, 1236  
 quantitative RT-PCR 144, 799  
 quiescent 302  
  
 Rad51 137  
 radiation 590, 699  
 radiotherapy 849, 977  
 raltitrexed 1230  
 randomised 279, 757, 862  
 randomised controlled trial 41  
 ras effectors 319  
 RASSF2 1395  
 rat carcinosarcoma 98  
 rational 54  
 Rb1 pathway 124  
 reactive metabolite(s) 89  
 real-time PCR 152, 793, 1301  
 real-time quantitative RT-PCR 986  
 real-time RT-PCR 565  
 recurrence of rectal carcinoma 131  
  
 redox cycling 89  
 referral and consultation 399  
 regional variation 520  
 regions of imbalance 1191  
 regulatory agencies 504  
 relative risk of death 571  
 REMARK 387  
 renal cell carcinoma 670, 757  
 reproductive factors 364  
 rest/activity function 1202  
 retinoid 310  
 retinoid signalling 310  
 reverse transcription-polymerase chain reaction 688  
 risk 838  
 risk assessment 590  
 RT-PCR 1157  
 RUNX3 1029  
 rural 1068  
  
 S-1 884  
 S100A4 1277  
 salvage chemotherapy 178  
 salvage therapy 412  
 scaffold 499  
 screening 376, 862, 1077  
 season of diagnosis 571  
 second primary cancers 159, 418  
 second-line treatment 763  
 SEER 1046  
 seminoma 1382  
 sentinel node biopsy 520  
 septin 499  
 sequential 54  
 serum phospholipids 1329  
 sex hormones 859  
 side effects 744  
 signal transduction 70  
 signalling 915  
 SIL 1068  
 single-strand conformation polymorphism 355  
 skin neoplasms 597  
 sleep quality 1202  
 small-cell lung cancer 1197  
 smoking 355, 1310  
 smoking cessation 1310  
 SNPs 493, 811  
 social difficulties 622  
 somatostatin receptors 1144  
 soybean products 15  
 specific induction 694  
 spheroid 302  
 squamous cell carcinoma 597  
 squamous cell head and neck cancer 279  
 stem cells 719, 855  
 SUIT-2 1024  
 superparamagnetic iron oxide 131  
 surgery 287  
 surrogate end point 195  
 surrogate markers 1215  
 survival 124, 372, 977, 1215  
  
 symptoms 905  
 synchronous colorectal cancer 472  
 synergism 319  
 systematic review 293, 825  
  
 T cells 248  
 TACE/ADAM17 1267  
 Taiwan 1057  
 tamoxifen 647  
 taxanes 173, 293  
 taxol 406  
 taxotere 173  
 T $\beta$ R11 1157  
 telephone 842  
 temozolomide 529, 1152  
 testicular cancer 200, 1307  
 testicular tumours 1382  
 testis-specific protein Y-encoded 458  
 TGF $\beta$  1029  
 TGF- $\beta$ 1 1157  
 thalidomide 613  
 therapy 1144  
 thrombosis 909  
 thyroglobulin mRNA 565  
 thyroid 464, 1175  
 thyroid cancer 565  
 thyroid neoplasm 1277  
 thyroid transcription factor 1 450  
 timing 627  
 tissue distribution 81  
 tissue microarray 137, 478, 1019  
 TNF $\alpha$  1024  
 toenail selenium 804  
 tolerability 208  
 topoisomerases 54, 60  
 topotecan 60  
 toxicity 1230  
 transcription factor 1285  
 transgenic mice 1137  
 treatment 552  
 treatment efficacy 744  
 triacylglycerol 639  
 trial conclusion 41  
 Tsp-1 933  
 tumorigenicity 1157  
 tumour 302, 979  
 tumour growth 1350  
 tumour marker 195, 387  
 tumour oxygenation 224  
 tyrosine kinase inhibitor 1334  
  
 UbcH10 464  
 ubiquitin-proteasome proteolysis 774  
 UFT 770  
 UK practice 1324  
 ulcerative colitis 331  
 unselected 1068  
 uracil-tegafur 770  
 urothelial cancer 544  
 urothelial carcinoma 242  
 uveal melanoma 1191  
  
 vaccination 1068  
 valspodar 46

- variability 208
- vascular disruptive agents 979
- vascular endothelial growth factor receptor 233
- vascular resistance 98
- VEGF 107, 924
- venous thromboembolism 838
- vincristine 1209
- viral load sensitivity 575
- vitamin D 571
- voltage-gated ion channels 1197
- waiting times 905
- weight gain 582
- weight history 582
- Western blot 144